The expression of PD1/PD-L1 in ovarian cancer and adjacent tissues and its relationship with clinical pathology and prognosis
Objective To investigate the expression of programmed death 1(PD1)/programmed death ligand-1(PD-L1)in ovarian cancer and adjacent tissues,and its relationship with clinical pathology and prognosis.Methods 120 ovarian cancer patients admitted to Cangzhou Central Hospital from December 2021 to December 2022 were selected for this study.The expression of PD1 and PD-L1 in cancer tissues and adja-cent tissues was examined.Multivariate logistic regression analysis and Kaplan-Meier analysis were performed to explore the relationship among PD1,PD-L1,clinical pathology and prognosis.Results Among the 120 pa-tients,there were 32(26.67%)cases that were PD1 positive(PD1 positive group)and 39(32.50%)cases that were PD-L1 positive cases(PD-L1 positive group).Simultaneous expression of PD1 and PD-L1 was ob-served in 30(25.00%)patients(expression group).No expression of PD1 or PD-L1 was observed in 79(65.83%)patients(non-expression group).There was no PD1 or PD-L1 expression in adjacent tissues.Statisti-cally significant differences were found in pathological types and FIGO staging between the PD1/PD-L1 posi-tive group and the PD1/PD-L1 negative group(P<0.05).Multivariate logistic regression analysis found that pathological type and FIGO stage were influencing factors of PD1 and PD-L1 expression(P<0.05).Out of 120 patients,39 experienced recurrences.The recurrence rates in the PD1 positive group,PD-L1 positive group,expression group and non-expression group were 50.00%,56.41%,60.00%and 12.68%,respectively.PFS of the four groups were(18.04±1.68)months,(17.96±1.42)months,(16.73±1.05)months and(20.06±1.75)months.Conclusion The expression of PD1 and PD-L1 in ovarian cancer tissues suggests a poor prog-nosis.Clinically,targeted measures should be taken for PD1 positive and PD-L1 positive patients to improve their prognosis.
Ovarian cancerProgrammed death 1Programmed death ligand 1Clinical pathology